Azzad Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Azzad Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Buy	4,630 +39	+0.8%	+$11.8K	0.12%	194
2026 Q1	$1.52M	Hold	4,591	–	–	0.15%	178
2025 Q4	$1.83M	Sell	4,591 -29	-0.6%	-$12.8K	0.18%	175
2025 Q3	$2.11M	Buy	4,620 +1,969	+74%	+$802K	0.21%	167
2025 Q2	$864K	Buy	+2,651	New	+$734K	0.09%	240
2023 Q3	–	Sell	-2,725	Closed	-$518K	–	303
2023 Q2	$518K	Buy	2,725 +11	+0.4%	+$2.18K	0.07%	271
2023 Q1	$544K	Buy	2,714 +19	+0.7%	+$3.99K	0.08%	265
2022 Q4	$641K	Buy	2,695 +24	+0.9%	+$5.12K	0.1%	237
2022 Q3	$535K	Buy	2,671 +5	+0.2%	+$954	0.05%	336
2022 Q2	$389K	Buy	2,666 +62	+2%	+$8.8K	0.04%	354
2022 Q1	$425K	Sell	2,604 -83	-3%	-$12.6K	0.06%	280
2021 Q4	$456K	Buy	+2,687	New	+$499K	0.06%	295

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Azzad Asset Management's ALNY Position: Q2 2026 in Review

Azzad Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.85% in Q2 2026, buying an estimated $11.8K and bringing the position to 4,630 shares worth $1.39M. The position accounts for 0.12% of the portfolio, ranked #194.

Azzad Asset Management first reported a position in ALNY in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.11M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Azzad Asset Management held 4,630 shares of Alnylam Pharmaceuticals worth $1.39M as of Q2 2026.
Azzad Asset Management bought 39 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $11.8K.
Alnylam Pharmaceuticals made up 0.12% of Azzad Asset Management's portfolio in Q2 2026, its #194 holding.
Azzad Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Azzad Asset Management's Alnylam Pharmaceuticals position peaked at $2.11M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Azzad Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.